Status check: Marketplace plans remain the weakest GLP-1 coverage channel heading into 2027

Obesity medications are not classified as an essential health benefit under the Affordable Care Act, which means insurers selling plans on the ACA Marketplace are not required to cover drugs like Wegovy, Zepbound, or Foundayo when they are prescribed for weight loss alone ^[1]. A review of all 300 carriers offering 2026 individual and family Marketplace plans found that only 26 of them cover GLP-1 medications for obesity, and that coverage is concentrated in just nine states ^[1].

Most of those 26 carriers also limit who can get the drugs covered. All but four restrict coverage to enrollees with a body mass index of 40 or higher, a threshold health insurance-focused outlets describe as roughly 240 pounds for a person of average height ^[1]. That is a stricter bar than the FDA's own approval criteria for these drugs, which generally allow use starting around a BMI of 30, or 27 with a weight-related health condition.

The number of people with any Marketplace plan that covers GLP-1s for obesity has been shrinking, not growing. Enrollment in plans offering this coverage fell from 3.6 million in 2024 to 2.8 million in 2026 ^[1]. That decline is happening even as demand for these drugs keeps rising: 12% of U.S. adults said in late 2025 they were currently using a GLP-1 medication, double the share reported 18 months earlier ^[1]. A separate 2024 analysis found the pattern was already stark — most Marketplace plans covered GLP-1s for diabetes, but only 1% covered Saxenda or Wegovy for weight loss, and none covered Zepbound for that purpose ^[1].

Marketplace enrollees also face a broader cost problem heading into 2027. Benchmark premiums, the second-lowest-cost silver plans used to calculate subsidies, rose by an average of 21.7% in 2026, a jump researchers at the Urban Institute and Commonwealth Fund called an aberration compared with recent years ^[2]. Reasons cited include the expiration of enhanced premium tax credits, new federal rules, and rising medical costs — including "increased intensity in utilization of certain treatments like new weight-loss drugs" ^[2]. Analysts also warn that policy changes from H.R. 1 taking effect in 2027 and 2028 could add further uncertainty and push premiums higher still ^[2].

Why it matters for patients

For people who buy their own coverage through the ACA Marketplace rather than getting insurance through an employer, Medicare, or Medicaid, this combination is a real financial squeeze. Someone hoping a Marketplace plan will pay for Wegovy, Zepbound, or Foundayo for weight loss faces long odds: fewer than one in ten carriers nationwide offer that coverage, it exists in only nine states, and most plans that do cover it require a BMI of 40 or above before paying a claim ^[1]. Coverage for diabetes treatment with drugs like Ozempic or Mounjaro is more widely available on formularies, but coverage specifically for obesity remains rare ^[1].

At the same time, overall Marketplace premiums are rising sharply, which affects what people pay for any plan, regardless of whether it covers GLP-1s ^[2]. Deductibles on silver plans already averaged around $5,000, and bronze plan deductibles around $7,500, before the 2026 premium increase ^[2]. People weighing whether to seek obesity treatment through Marketplace coverage should know that even finding a qualifying plan does not guarantee an affordable path to the medication, since prior authorization and BMI cutoffs remain common hurdles ^[1].

What happens next

2027 benchmark premiums are set to rise again, and further increases could follow, since federal policy changes passed in H.R. 1 are scheduled to phase in during 2027 and 2028, which analysts say may add more uncertainty for insurers pricing Marketplace plans ^[2]. It is not yet known whether more carriers will begin covering GLP-1s for obesity as prices or competition shift, or whether the shrinking enrollment trend in plans that do cover these drugs will continue.